Product Description
CSPC is developing tg-103, a subcutaneous agent for Type 2 Diabetes
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CSPC
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 12
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Obesity|Overweight|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05997576 |
SYSA1803-013 | P3 |
Completed |
Overweight|Obesity |
2025-02-17 |
13% |
2025-08-13 |
|
NCT06258148 |
SYSA1803-010 | P3 |
Active, not recruiting |
Type 2 Diabetes |
2026-03-01 |
27% |
2025-08-13 |
Primary Endpoints|Start Date |
CTR20233558 |
CTR20233558 | P1 |
Completed |
Type 2 Diabetes |
2024-04-21 |
2025-04-29 |
||
CTR20232978 |
CTR20232978 | P1 |
Completed |
Type 2 Diabetes |
2024-01-19 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20240075 |
CTR20240075 | P2 |
Completed |
Obesity |
2024-12-06 |
2025-05-17 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06226090 |
SYSA1803-017 | P2 |
Completed |
Overweight|Obesity |
2024-09-26 |
37% |
2025-05-15 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20220751 |
CTR20220751 | P2 |
Completed |
Type 2 Diabetes |
2023-10-10 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20212332 |
CTR20212332 | P2 |
Completed |
Type 2 Diabetes |
2023-06-30 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20220498 |
CTR20220498 | P2 |
Completed |
Obesity|Overweight |
2023-04-12 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20243650 |
CTR20243650 | P1 |
Completed |
Type 2 Diabetes |
2025-01-24 |
2025-04-29 |
||
NCT06235086 |
SYSA1803-009 | P3 |
Active, not recruiting |
Type 2 Diabetes |
2026-03-30 |
38% |
2025-08-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
CTR20240958 |
CTR20240958 | P1 |
Completed |
Type 2 Diabetes |
2024-11-26 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |